# Natalizumab Subcutaneous Immunogenicity and Safety Study

> **NCT02142192** · PHASE2 · TERMINATED · sponsor: **Biogen** · enrollment: 2 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** natalizumab

## Key facts

- **NCT ID:** NCT02142192
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12-01
- **Primary completion:** 2015-06-04
- **Final completion:** 2015-06-04
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Sponsor's decision.
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02142192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02142192, "Natalizumab Subcutaneous Immunogenicity and Safety Study". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02142192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*